9.35
0.24 (2.63%)
| Previous Close | 9.11 |
| Volume | 457,965 |
| Price / Earnings (Forward) | 3.46 |
| Price / Sales | 2.07 |
| Price / Book | 3.44 |
| 52 Weeks Range |
| Profit Margin | 16.36% |
| Operating Margin (TTM) | 8.66% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | 5.10% |
| Quarterly Earnings Growth (YOY) | 57.40% |
| Total Debt/Equity (MRQ) | 63.55% |
| Current Ratio (MRQ) | 1.53 |
| Operating Cash Flow (TTM) | 31.28 M |
| Levered Free Cash Flow (TTM) | 19.67 M |
| Return on Assets (TTM) | 11.35% |
| Return on Equity (TTM) | 51.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Puma Biotechnology Inc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.94 |
|
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.87% |
| % Held by Institutions | 65.68% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |